SAR 447754
Alternative Names: SAR-447754Latest Information Update: 17 Mar 2026
At a glance
- Originator Sanofi-Aventis Recherche & Developpement
- Class Anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Atopic dermatitis
Most Recent Events
- 25 Feb 2026 Phase-I clinical trials in Atopic dermatitis in Belgium (unspecified route) (CTIS2025-523826-41-00)